De-escalating Surgery Among Patients with HER2+and Triple Negative Breast Cancer

被引：2

作者：

Tasoulis, Marios-Konstantinos ^{[1
,2
]}

Heil, Joerg ^{[3
]}

Kuerer, Henry M. ^{[4
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Breast Surg Unit, Fulham Rd, London SW3 6JJ, England

[2] Inst Canc Res, Div Breast Canc Res, Old Brompton Rd, London SW7 3RP, England

[3] Heidelberg Univ Hosp, Univ Breast Unit, Dept Obstet & Gynecol, Heidelberg, Germany

[4] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA

来源：

CURRENT BREAST CANCER REPORTS | 2022年 / 14卷 / 04期

关键词：

Surgical de-escalation; Breast surgery; Triple negative; HER2; positive; Breast cancer; PATHOLOGICAL COMPLETE RESPONSE; SENTINEL NODE BIOPSY; 20-YEAR FOLLOW-UP; NEOADJUVANT CHEMOTHERAPY; RADICAL-MASTECTOMY; MULTICENTER; TRIAL; IDENTIFICATION; AXILLA; IMPACT;

D O I：

10.1007/s12609-022-00453-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of Review De-escalation of surgery has been central in the evolution of multidisciplinary management of breast cancer. Advances in oncology and increasing use of neoadjuvant chemotherapy (NACT) have opened opportunities for further surgical de-escalation especially for HER2 + and triple negative (TN) disease. The aim of this review is to discuss the recent data on de-escalation of surgery as well as the future directions. Recent Findings Patients with TN and HER2 + breast cancer with excellent response to NACT would be the ideal candidates for surgical de-escalation. Post-NACT image-guided biopsy, potentially combined with machine learning algorithms, may accurately identify patients achieving pathologic complete response that would be eligible for clinical trials assessing safety of omission of breast and axillary surgery. Multidisciplinary research is required to further support results of preliminary studies. Current data point towards a future when even less or no surgery may be required for exceptional responders.

引用

页码：135 / 141

页数：7

共 55 条

[31] Survival Outcomes for Patients With Clinical Complete Response After Neoadjuvant Chemotherapy: Is Omitting Surgery an Option? [J].

Ozkurt, Enver ;

Sakai, Takehiko ;

Wong, Stephanie M. ;

Tukenmez, Mustafa ;

Golshan, Mehra .

ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (10) :3260-3268

[32] Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery [J].

Pfob, Andre ;

Sidey-Gibbons, Chris ;

Rauch, Geraldine ;

Thomas, Bettina ;

Schaefgen, Benedikt ;

Kuemmel, Sherko ;

Reimer, Toralf ;

Hahn, Markus ;

Thill, Marc ;

Blohmer, Jens-Uwe ;

Hackmann, John ;

Malter, Wolfram ;

Bekes, Inga ;

Friedrichs, Kay ;

Wojcinski, Sebastian ;

Joos, Sylvie ;

Paepke, Stefan ;

Degenhardt, Tom ;

Rom, Joachim ;

Rody, Achim ;

van Mackelenbergh, Marion ;

Banys-Paluchowski, Maggie ;

Grosse, Regina ;

Reinisch, Mattea ;

Karsten, Maria ;

Golatta, Michael ;

Heil, Joerg .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17) :1903-+

[33] Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy [J].

Pfob, Andre ;

Sidey-Gibbons, Chris ;

Lee, Han-Byoel ;

Tasoulis, Marios Konstantinos ;

Koelbel, Vivian ;

Golatta, Michael ;

Rauch, Gaiane M. ;

Smith, Benjamin D. ;

Valero, Vicente ;

Han, Wonshik ;

MacNeill, Fiona ;

Weber, Walter Paul ;

Rauch, Geraldine ;

Kuerer, Henry M. ;

Heil, Joerg .

EUROPEAN JOURNAL OF CANCER, 2021, 143 :134-146

[34] Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints [J].

Rauch, Gaiane M. ;

Kuerer, Henry M. ;

Adrada, Beatriz ;

Santiago, Lumarie ;

Moseley, Tanya ;

Candelaria, Rosalind P. ;

Arribas, Elsa ;

Sun, Jia ;

Leung, Jessica W. T. ;

Krishnamurthy, Savitri ;

Yang, Wei T. .

ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (07) :1953-1960

[35] Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial [J].

Reimer, Toralf ;

Glass, Aenne ;

Botteri, Edoardo ;

Loibl, Sibylle ;

Gentilini, Oreste D. .

CANCERS, 2020, 12 (12) :1-12

[36] Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? [J].

Ring, A ;

Webb, A ;

Ashley, S ;

Allum, WH ;

Ebbs, S ;

Gui, G ;

Sacks, NP ;

Walsh, G ;

Smith, IE .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4540-4545

[37] Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy [J].

Samiei, Sanaz ;

van Nijnatten, Thiemo J. A. ;

de Munck, Linda ;

Keymeulen, Kristien B. M., I ;

Simons, Janine M. ;

Kooreman, Loes F. S. ;

Siesling, Sabine ;

Lobbes, Marc B., I ;

Smidt, Marjolein L. .

ANNALS OF SURGERY, 2020, 271 (03) :574-580

[38]

Schmid P., 2020, NEW ENGL J MED, V382, P9

[39] Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) [J].

Schneeweiss, A. ;

Chia, S. ;

Hickish, T. ;

Harvey, V. ;

Eniu, A. ;

Hegg, R. ;

Tausch, C. ;

Seo, J. H. ;

Tsai, Y. -F. ;

Ratnayake, J. ;

McNally, V. ;

Ross, G. ;

Cortes, J. .

ANNALS OF ONCOLOGY, 2013, 24 (09) :2278-2284

[40] Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance) [J].

Sikov, William M. ;

Berry, Donald A. ;

Perou, Charles M. ;

Singh, Baljit ;

Cirrincione, Constance T. ;

Tolaney, Sara M. ;

Kuzma, Charles S. ;

Pluard, Timothy J. ;

Somlo, George ;

Port, Elisa R. ;

Golshan, Mehra ;

Bellon, Jennifer R. ;

Collyar, Deborah ;

Hahn, Olwen M. ;

Carey, Lisa A. ;

Hudis, Clifford A. ;

Winer, Eric P. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (01) :13-U34

← 1 2 3 4 5 6 →